Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM).
Richard D. Carvajal
No relevant relationships to disclose
Jeffrey Alan Sosman
No relevant relationships to disclose
Fernando Quevedo
No relevant relationships to disclose
Mohammed M. Milhem
No relevant relationships to disclose
Anthony Michael Joshua
No relevant relationships to disclose
Ragini Reiney Kudchadkar
No relevant relationships to disclose
Gerald P. Linette
No relevant relationships to disclose
Thomas Gajewski
No relevant relationships to disclose
Jose Lutzky
No relevant relationships to disclose
David H. Lawson
No relevant relationships to disclose
Christopher D. Lao
No relevant relationships to disclose
Patrick J. Flynn
No relevant relationships to disclose
Mark R. Albertini
No relevant relationships to disclose
Takami Sato
No relevant relationships to disclose
Daniel Paucar
No relevant relationships to disclose
Katherine S. Panageas
No relevant relationships to disclose
Mark Andrew Dickson
No relevant relationships to disclose
Jedd D. Wolchok
No relevant relationships to disclose
Paul B. Chapman
No relevant relationships to disclose
Gary K. Schwartz
No relevant relationships to disclose